

Cardiac arrhythmia following acute myocardial infarction: a retrospective analysis of 27,648 hospitalized patients in a tertiary heart hospital

Nidal Asaad,¹ Ayman El-Menyar,^{2,3} Rajvir Singh,⁴ Betsy Varughese,⁵ Shahul Hameed Khan,¹ Hajar AlBinali,¹ Jassim Al Suwaidi¹

¹Cardiology Department, Heart Hospital, Hamad Medical Corporation, Doha; ²Vascular Surgery, Clinical Research, Hamad Medical Corporation, Doha; ³Clinical Medicine, Weill Cornell Medicine, Doha; ⁴Cardiovascular Research, Heart Hospital, Hamad Medical Corporation, Doha; ⁵Internal Medicine Research, Hamad General Hospital, Doha, Qatar

Abstract

Arrhythmia frequently complicates acute myocardial infarction (AMI) and contributes to high morbidity and mortality. We aimed to investigate the prevalence, risk factors, and impact of cardiac arrhythmias in AMI patients at a tertiary heart hospital. This retrospective observational study included AMI patients who were admitted between January 1991 and May 2022. Patients' data were analyzed and compared according to the absence or presence of cardiac arrhythmias post-AMI. We hypothesized that arrhythmias are associated with higher mortality following AMI. During the study, 27,648 patients were hospitalized with AMI, of whom 2118 (7.7%) developed arrhythmia. Patients who developed arrhythmia had a higher average age compared to those without arrhythmia (57.2 vs. 54.8 years, $p=0.001$), and a larger proportion were male compared to female patients (85.2% vs. 14.8%, $p=0.001$). Atrial fibrillation was observed in 383 patients (18.1%). Ventricular tachycardia was found in 461 (21.8%), and ventricular fibrillation occurred in 526 patients (24.8%). Complete heart block was developed in 286 (13.5%) patients, 1st-degree atrioventricular (AV) block in 36 (1.7%), 2nd-degree AV block in 138 (6.5%), left bundle branch block in 81 (3.8%), and right bundle branch block in 118 (5.6%). The rate of β -blocker use has increased in the arrhythmias group at discharge compared to the on-admission rate (55.7% vs. 32.5%). However, it remained sub-optimal. Arrhythmias were associated with longer hospital stays and five times higher hospital mortality than the non-arrhythmia group. Multivariable logistic regression analysis indicated that arrhythmia was associated with increased mortality risk three times following AMI (adjusted odds ratio 3.01; 95% confidence interval 2.42-3.75, $p=0.001$). Almost one-tenth of patients hospitalized with AMI in Qatar developed arrhythmia with variable outcomes; however, the in-hospital mortality remained high. Addressing the risk factors and optimizing the prevention and treatment of AMI and arrhythmias is crucial to improving clinical outcomes. This study may underestimate the incidence of arrhythmias post-AMI as it did not report all types.

Key words: arrhythmias, acute myocardial infarction, coronary, outcome, heart.

Correspondence to: Ayman El-Menyar, Vascular Surgery, Clinical Research, Hamad Medical Corporation, Doha, Qatar.
E-mail: aymanco65@yahoo.com

Introduction

Arrhythmias (dysrhythmias) frequently occur as complications following an acute myocardial infarction (AMI) and could contribute to increased morbidity and mortality [1]. Despite significant advances in medical therapy, arrhythmia continues to have an adverse impact on the prognosis and outcomes [2]. In addition, arrhythmia associated with AMI often puts a tremendous burden on healthcare systems and patients [1,3]. Most AMI-related deaths attributed to arrhythmias encompass bradyarrhythmia, supraventricular tachyarrhythmias, and ventricular arrhythmias (VA) [4]. The reopening of an infarct-related artery in the acute phase of AMI further escalates the likelihood of significant arrhythmia as part of reperfusion injury, compounding the mortality risk [5].

Multiple studies have investigated the prevalence of cardiac arrhythmia in AMI patients and found variable results depending on the patient population, studying the extent of myocardial damage

and other risk factors involved [4,6]. Among the lethal arrhythmias, VA are the most feared complication that can initiate or worsen cardiac failure or result in sudden cardiac death (SCD), and they tend to manifest in the first 48 hours following the onset of AMI [7-9]. Numerous risk factors, including advanced age and pre-existing cardiac conditions, hypertension, diabetes mellitus, and multivessel disease, have been associated with the occurrence of cardiac arrhythmias [4,10]. Additionally, the timing and efficacy of reperfusion therapy, with failure or delayed reperfusion, have been linked to a higher incidence of arrhythmias [1,11].

The underlying causes of cardiac arrhythmias in AMI patients are intricate and multifaceted. Electrical instability, cardiac tissue heterogeneity, and changes in ion channel function are all effects of ischemia-induced myocardial damage that result in the development of a proarrhythmic substrate [12]. These electrophysiological abnormalities result in various arrhythmias, including ventricular tachycardia and ventricular fibrillation (VF), which can exacerbate symptoms related to AMI and cause SCD [13,14].



Early identification and effective management of arrhythmias are critical for reducing complications and improving the overall prognosis of patients with AMI. A multidisciplinary approach is needed, involving prompt and early diagnosis, risk stratification, and timely intervention. Antiarrhythmic drugs, including β -blockers, amiodarone, and lidocaine, are commonly employed to control arrhythmias during the acute phase [15]. Additionally, early revascularization through percutaneous coronary intervention (PCI) or thrombolytic therapy is used to restore coronary blood flow and limit myocardial injury [16-18]. The implantation of cardioverter-defibrillators for high-risk patients is warranted to prevent SCD in selected cases [19].

Although patients remain susceptible to cardiac arrhythmias and sudden death, the recovery phase following AMI has garnered less attention [4]. There is a significant link between early post-hospital mortality and the occurrence of arrhythmias during the hospital stay [20]. Hence, there is an urgent need for more proactive identification and management of cardiac arrhythmias in individuals experiencing AMI. Understanding and addressing the risk factors helps the risk stratification and devising targeted interventions to improve patient outcomes, ultimately reducing the burden of cardiac arrhythmia in AMI patients. Therefore, this study aims to investigate the prevalence, risk factors and impact of cardiac arrhythmias in AMI patients at a tertiary heart hospital. We hypothesized that arrhythmias are associated with higher mortality following AMI.

Materials and Methods

Sample population

The study used retrospective cohort data of patients in the coronary care unit (CCU) registry at the Heart Hospital in Qatar. The CCU data registry with cardiovascular diseases is approved by IRB, Medical Research Center, Hamad Medical Corporation (HMC) (MRC#11355/11). A detailed description of the registry is given elsewhere [21]. Data were collected between January 1991 to May 2022. The Heart Hospital at HMC (a governmental, not-for-profit institution) is a tertiary hospital that caters to more than 95% of the cardiac inpatient and outpatient medical and surgical care needs of nationals and residents of Qatar.

The patients' physicians collected data from each patient at the time of discharge on a predefined coded record form (CRF). Recorded data were checked and validated by a research coordinator in the department. Approximately 40% of Qatar's population are Arabs, including Qatari nationals, and 60% are non-Arabs. The CRF included history, along with information regarding risk factors for CHD, indications for coronary angiography, and the angiographic findings of each patient. The presence of diabetes mellitus was determined by the documentation in the patient's previous or current medical record of a diagnosis of diabetes mellitus that had been treated with medication or insulin. The presence of hyperlipidemia was determined by fasting cholesterol >5.2 mmol/L in the patient's medical record or any history of hyperlipidemia treatment by the patient's physician. The presence of hypertension was determined by documentation in the medical record of hypertension or by determining whether the patient was receiving treatment from their physician. The diagnosis of acute coronary syndrome, including AMI, was based on the final decision of the assigned consultants based on clinical, electrocardiographic, laboratory, and echocardiographic data [22]. The study included all adult male and female patients admitted to the cardiology department with AMI documented on

admission. Patients with incomplete data were excluded. The type of arrhythmia was documented as bradyarrhythmia [sinus bradycardia or any atrioventricular (AV) block], tachyarrhythmia including atrial, supraventricular, and VA [1].

Statistical analysis

Descriptive statistics were calculated for categorical variables and interval variables in the form of frequency with percentages for categorical variables and mean, standard deviation, or interquartile range for interval variables in the study. Chi-square tests were used to see the association of categorical variables between the arrhythmia vs. non-arrhythmia group. Student t-tests or Mann-Whitney U tests were applied to see significant mean/median level differences between the two groups for interval variables. Multivariate binary logistic regression was used to find the risk of arrhythmia patients for in-hospital mortality with other important risk factors. Receiver operating characteristic (ROC) curve analysis of the predictive regression model for in-hospital mortality in AMI patients. A two-tailed p-value (≤ 0.05) was considered at a statistically significant level. The SPSS 29.0 statistical package (IBM, Armonk, NY, USA) was used for the analysis.

Results

Overall findings

During the study period, 27,648 patients were hospitalized with AMI, of whom 2118 (7.7%) developed arrhythmias. Table 1 describes the demographic and risk factors associated with cardiac arrhythmia in patients with AMI. Patients who developed arrhythmia post-AMI had a higher average age compared to those without arrhythmia (57.2 years vs. 54.8 years, $p=0.001$), and a larger proportion of males developed arrhythmia compared to females (85.2% vs. 14.8%, $p=0.001$).

Risk factors such as diabetes mellitus (DM), hypertension, family history, obesity, and CRF were not found to be significant between patients with arrhythmia and those without arrhythmia. Hospital deaths and median days of hospital stay were significantly higher in arrhythmia patients than in non-arrhythmia patients ($p=0.001$). Other cardiac conditions, such as aortic insufficiency (AI), aortic stenosis (AS), and mitral regurgitation (MR), showed mixed results, with some differences being statistically significant. Congestive heart failure (CHF) was more common in patients with arrhythmia compared to those without arrhythmia (11.9% vs. 6.7%, $p=0.001$). Table 2 shows the differences in various lab parameters and procedures between AMI patients with and without arrhythmia. Notable differences were observed with hemoglobin, B-type natriuretic peptide (BNP), and creatine kinase-MB (CK-MB) levels, suggesting potential associations with arrhythmia development in AMI patients. However, no significant differences were found in fasting blood sugar, creatinine, triglycerides, and ejection fraction percentages between the two groups.

Types of arrhythmias

Atrial fibrillation (AF) was observed in 383 patients, accounting for 18.1% of the sample. Ventricular tachycardia (VT) was observed in 461 (21.8%), and VF occurred in 526 patients (24.8%) (Table 3). Complete heart block happened in 286 (13.5%), 1st-degree AV block in 36 (1.7%), 2nd-degree AV block in 138 (6.5%), left bundle branch block (LBBB) in 81 (3.8%), and right bundle branch block (RBBB) in 118 (5.6%).



Table 1. Demographic, risk factors, and outcome of cardiac arrhythmia in acute myocardial infarction patients.

Variable	Category	No arrhythmia 25,530 (92.3%)	Arrhythmia 2118 (7.7%)	p
Age in years	—	54.8±12.2	57.2±13.2	0.001
Gender, n (%)	Male	22,515 (88.2)	1803 (85.2)	0.001
	Female	3014 (11.8)	314 (14.8)	
Nationality, n (%)	Qatari	5309 (20.8)	559 (26.4)	0.001
STEMI, n (%)	Yes	12,192 (51.3)	1401 (70.6)	0.001
NSTEMI, n (%)	Yes	11,597 (48.7)	583 (29.4)	0.001
Diabetes mellitus, n (%)	Yes	11,332 (44.4)	981 (46.3)	0.09
Hypertension, n (%)	Yes	11,105 (43.5)	885 (41.8)	0.13
Dyslipidemia, n (%)	Yes	3577 (14.0)	245 (11.6)	0.002
Family history, n (%)	Yes	792 (3.1)	51 (2.4)	0.07
Obesity, n (%)	Yes	1062 (4.2)	100 (4.7)	0.22
Chronic renal failure, n (%)	Yes	1309 (5.1)	123 (5.8)	0.18
Smoking, n (%)	Yes	12,558 (49.2)	1004 (47.4)	0.001
Aortic insufficiency, n (%)	Yes	38 (0.1)	7 (0.3)	0.05
Aortic stenosis, n (%)	Yes	746 (2.9)	69 (3.3)	0.38
Mitral stenosis, n (%)	Yes	150 (0.6)	22 (1.0)	0.01
Hospital death, n (%)	Yes	1058 (4.1)	455 (21.5)	0.001
Hospital length of stay days, n (IQR)	-	-	4 (3-6)	6 (4-11)0.001

STEMI, ST-segment elevation myocardial infarction; NSTEMI, non- ST-segment elevation myocardial infarction; IQR, interquartile range.

Table 2. Lab parameters and procedures in acute myocardial infarction patients.

Variable	No arrhythmia 25,530 (92.3%)	Arrhythmia 2118 (7.7%)	p
Hemoglobin level (IQR)	13.9 (12-15)	13 (11-14.7)	0.001
Fasting blood sugar (IQR)	7 (6-10)	7 (6-10.7)	0.31
Serum creatinine (IQR)	88 (75-105)	96 (81-128)	0.09
BNP value (IQR)	267 (23-1564)	760 (54-3703)	0.002
CK-MB (IQR)	47.8 (11.3-160)	93 (15-311)	0.001
LVEF% (IQR)	47 (40-54)	42 (33-50)	0.05
Coronary angiogram, n (%)	3786 (14.8)	341 (16.1)	0.12
Swan Ganz, n (%)	109 (0.4)	55 (2.6)	0.001
PTCA/PCI, n (%)	6472 (25.4)	455 (21.5)	0.001
Holter monitoring, n (%)	274 (1.1)	85 (4.0)	0.001
Echocardiography, n (%)	12078 (47.3)	984 (46.5)	0.45

IQR, interquartile range; BNP, B-type natriuretic peptide; CK-MB, creatine kinase-MB; LVEF, left ventricular ejection fraction ; PTCA, percutaneous coronary angioplasty; PCI, percutaneous coronary intervention.

Table 3. Type of arrhythmia in acute myocardial infarction patients.

Type of arrhythmia	n (%)
Atrial fibrillation	383 (18.1)
Ventricular tachycardia	461 (21.8)
Ventricular fibrillation	526 (24.8)
Complete heart block	286 (13.5)
1° heart block	36 (1.7)
2° heart block	138 (6.5)
Left bundle branch block	81 (3.8)
Right bundle branch block	118 (5.6)



Medications

Tables 2 and 4 show various procedures and treatments for patients with AMI, categorized by the presence or absence of arrhythmia. On-admission medications such as β -blockers, calcium channel blockers, angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), aspirin, clopidogrel, and low-molecular-weight heparins (LMWH) were less frequently administered to patients with arrhythmia upon admission, reflecting variations in initial treatment strategies tailored to the presence or absence of arrhythmia in AMI patients.

At discharge, β -blockers (77.6%), calcium channel blockers (12.4%), ACEI/ARB (52.9%), aspirin (92.6%), clopidogrel (58.9%), and statins (70.8%) were significantly higher in AMI with arrhythmia patients than in those who were not having arrhythmia,

whereas warfarin (3.1%) and diuretics (19.6%) were lower in the arrhythmic group.

Predictors of mortality

Table 5 reveals the results of a multivariate logistic regression analysis to identify factors associated with in-hospital mortality in AMI patients. Patients who have experienced arrhythmia have a significantly higher risk of in-hospital mortality after adjusting to other independent variables. The adjusted odds ratio of 3.01 indicated that these patients have more than three times the odds of in-hospital mortality compared to those without arrhythmia. ROC (Figure 1) demonstrated a high discriminative ability with an area under the curve of 0.86 (95% confidence interval: 0.85-0.87, $p=0.001$), suggesting that the model effectively distinguishes between patients who will survive and those who will not during their hospitalization.

Table 4. Medications of acute myocardial infarction patients.

Variable	No Arrhythmia 25,530 (92.3%)	Arrhythmia 2118 (7.7%)	p
Admission medications, n (%)			
β -blocker	12,471 (48.8)	688 (32.5)	0.001
Calcium channel	3606 (14.1)	185 (8.7)	0.001
ACEI/ARB	10,497 (51.0)	624 (38.4)	0.001
Aspirin	24,065 (94.3)	1865 (88.1)	0.001
Clopidogrel	16,074 (63.0)	1129 (53.3)	0.001
Warfarin	290 (1.1)	41 (1.9)	0.001
LMW Heparin	7771 (30.4)	397 (18.7)	0.001
Discharge medications, n (%)			
β -blocker	19,819 (77.6)	1180 (55.7)	0.001
Calcium channel blocker	3154 (12.4)	172 (8.1)	0.001
ACEI/ARB	13,493 (52.9)	885 (41.8)	0.001
Aspirin	23,653 (92.6)	1549 (73.1)	0.001
Clopidogrel	15,039 (58.9)	922 (43.5)	0.001
Warfarin	793 (3.1)	140 (6.6)	0.001
Diuretics	4997 (19.6)	520 (24.6)	0.001
Statins	18,072 (70.8)	1135 (53.6)	0.001

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

Table 5. Multivariate logistic regression analysis for in-hospital mortality in AMI patients.

Variable	Odds ratio	95% confidence interval	p
Age in years	1.05	1.04-1.06	0.001
Sex Male	0.58	0.48-0.72	0.001
Nationality Qatari	2.05	1.71-2.47	0.001
Diabetes mellitus	1.25	1.02-1.53	0.03
Hypertension	1.35	1.10-1.66	0.006
Dyslipidemia	0.80	0.64-0.98	0.03
Obesity	1.10	0.77-1.56	0.62
Chronic renal failure	1.62	1.30-2.0	0.001
LVEF%	0.94	0.93-0.95	0.001
Arrhythmia	3.01	2.42-3.75	0.001

LVEF, left ventricular ejection fraction.






Figure 1. Receiver operating characteristic (ROC) curve for in-hospital mortality in acute myocardial infarction patients and its C-statistics.

Discussion

This study describes the incidence, types, and outcomes of dysrhythmias following AMI in a large-scale population. This is a unique study from the Arab Middle Eastern countries that is characterized by high cardiovascular risk factors such as DM, hypertension, obesity, and dyslipidemia [23,24]. Also, the incidence of AMI in Qatar is high [25]. This study showed that dysrhythmias occur in almost 8% of post-AMI cases and are associated with longer hospital stays and a 5 times higher hospital mortality rate than the non-dysrhythmia group. However, this study may underestimate the incidence of arrhythmia post-AMI, as it did not report all types, such as premature ventricular ectopic (PVC). The rate of receiving β -blockers has increased in the arrhythmias group at discharge compared to the on-admission rate (55.7% vs. 32.5%). However, it remains sub-optimal. The most common types of dysrhythmias were VF (25%), VT (22%), AF (18%), and CHB (13.5%). The occurrence of dysrhythmia post-MI was an independent predictor of mortality with an odds ratio of 3.0. The true incidence of arrhythmia post-AMI is broadly varying in literature because of the definition of arrhythmias used in the study, the timing of the event in relation to the onset of AMI, the reperfusion therapy used, the fatality of arrhythmias (lethal vs. non-lethal), medications on admissions, whether sinus tachycardia or bradycardia were included and data documentation.

This study also showed an association between age and the development of post-AMI arrhythmia, as patients who experienced

arrhythmias were older than those without arrhythmia. These results align with the findings of previous studies that have identified age as a significant risk factor for arrhythmias in various cardiac conditions [26-29]. Gender differences also showed an association with a larger proportion of male patients developing arrhythmias compared to female patients [26,27]. The prevalence of arrhythmia was higher among Qatari patients with AMI compared to others.

Although the differences were not significant, comorbidities such as diabetes mellitus, obesity, and chronic renal failure were found more frequently in AMI patients with arrhythmia than in those who had no arrhythmia. However, paradoxical results were found in AMI patients with hypertension and a family history of AMI. Furthermore, dyslipidemia was significantly more common in AMI patients without arrhythmia, highlighting the need for a better understanding of the unique risk factors relevant to the specific patient population [30,31].

In this study, we also found that patients with arrhythmia experienced significantly higher rates of CHF, hospital deaths, and longer median hospital stays compared to those without arrhythmia [32-34]. On exploring the relationship between arrhythmias and other cardiac conditions, such as AI, AS, and MR, these conditions were more common in patients with arrhythmia compared to those without, which shows the intricate interconnections between various cardiac conditions and arrhythmias and brings out the significance of a holistic approach in managing post-MI patients with arrhythmias.

Our study showed that AF occurred in 18.1% of cases, VT in 21.8%, VF in 24.8%, and complete heart block in 13.5% of patients. These results align with existing literature emphasizing the association between arrhythmia and MI and its contribution to increased morbidity and mortality [35,36]. Some studies highlighted the clinical significance of heart blocks in this population, and the presence of 1° and 2° blocks constitutes the spectrum of conduction disturbances observed in AMI patients [37]. In addition, RBBB was found more than LBBB. RBBB is associated with more severe symptoms and higher incidents of complete occlusion of infarct-related artery and had primary PCI treatment compared with LBBB [38].

We also analyzed the relationship between the laboratory parameters and found significantly lower hemoglobin levels and reduced EF in AMI patients with arrhythmia. Lower hemoglobin levels have been associated with adverse cardiovascular events [39], and reduced EF is a risk factor for arrhythmia post-AMI [40]. BNP levels are elevated in AMI patients with arrhythmia compared to those without arrhythmia. CK-MB elevation has been linked to larger infarct sizes and adverse cardiac events [41], whereas elevated BNP is associated with increased cardiovascular events and mortality in AMI patients [42-45].

Patients without arrhythmias received coronary interventions more frequently than those with arrhythmias, which probably benefits these patients from early revascularization in reducing arrhythmias and improving overall prognosis in AMI patients [46,47].

The AMI patients without arrhythmia received significantly more β -blockers, calcium channel blockers, ACEI/ARB, aspirin, clopidogrel, and LMWHs during admission and discharge. β -blockers have traditionally been used to lower the myocardial oxygen demand and enhance outcomes after AMI [48]. These medications are known for their antiarrhythmic properties and cardiovascular benefits and are fundamental in post-AMI management [49,50]. Due to their proven effects on the cardiovascular system, ACE inhibitors are helpful in post-AMI management, especially in reducing mortality and arrhythmia post-AMI [51-53]. Early use of β -blockers,



statins and ACEI/ARB (if no contraindication), treatment of electrolyte imbalance, and early revascularization are important targets after AMI [54]. Although it is out of the study scope, the role of catheter ablation for VA as a therapeutic strategy is of interest, and exploring its utility in reducing arrhythmia burden and improving survival rates would add depth to the therapeutic considerations. Most ablations are performed post-MI and for intractable, drug-refractory arrhythmias (after treating the underlying ischemia), this will reduce the recurrence rate of VA [55].

In this study, we also observed that advanced age, diabetes mellitus, hypertension, and chronic renal failure are associated with a higher risk of in-hospital mortality in patients with AMI. On adjusting all other factors, multivariate logistic regression analysis showed that arrhythmia had a three-fold higher risk of in-hospital mortality in AMI patients. Shah *et al.* reported that the incidence of arrhythmia within 24 hours of hospitalization is high in patients with AMI, even in those who undergo primary PCI, and is associated with an increased rate of in-hospital mortality (15%) [56]. Chronic renal failure and arrhythmia are also identified as significant predictors of in-hospital mortality, which highlights the importance of managing comorbidities to improve outcomes in AMI patients [57,58]. Furthermore, the pathophysiological mechanism of arrhythmias is of value for management; for example, intramural re-entry causes arrhythmia during an ischemia event, while triggered activity is the main mechanism during the reperfusion stage [55]. The role of strain imaging, cardiac magnetic resonance imaging, and nuclear imaging in stratifying arrhythmic risk and decision-making is of current interest. Radionuclide imaging helps visualization and quantification of underlying pathophysiological processes of dysrhythmias [59]. Moreover, cardiac autonomic innervation imaging is a promising tool for directly evaluating arrhythmic risk [59].

Limitations

The risk of selection bias limits the retrospective design of this study. Moreover, being a single-center study limits the generalizability of the findings. Other limitations include lack of documentation of time from the onset of AMI, time to treat AMI, time of the onset of arrhythmia, and coronary culprit arrhythmia correlation. Also, the incidence of arrhythmia in each type and location of AMI and follow-up are not captured. The study did not include all kinds of dysrhythmias; however, it documented the most common and important types.

Conclusions

Almost one-tenth of patients hospitalized with AMI in Qatar developed arrhythmias with variable outcomes; however, in-hospital mortality remained high. Addressing the risk factors and optimizing the prevention and treatment of AMI and arrhythmias is crucial to improving clinical outcomes. However, this study may underestimate the incidence of arrhythmia post-AMI as it did not report all types, such as PVCs.

References

1. Frampton J, Ortengren AR, Zeitler EP. Arrhythmias after acute myocardial infarction. *Yale J Biol Med* 2023;96:83-94.
2. Mueed A, Khatl S, Ashraf J, et al. Arrhythmia in acute myocardial infarction: a six-month retrospective analysis from the national institute of cardiovascular diseases. *Cureus* 2020;12:e11322.
3. Aufderheide TP. Arrhythmias associated with acute myocardial infarction and thrombolysis. *Emerg Med Clin North Am* 1998; 16:583-600, viii.
4. Shah JA, Naz F, Kumar R, et al. Incidence of cardiac arrhythmias in acute myocardial infarction patients undergoing primary percutaneous coronary intervention and associated outcomes during the first 24 hours. *Cureus* 2021;13:e12599.
5. Ohlow MA, Geller JC, Richter S, et al. Incidence and predictors of ventricular arrhythmias after ST-segment elevation myocardial infarction. *Am J Emerg Med* 2012;30:580-6.
6. Sharma R, Chowdhary I, Sharma A. Arrhythmia and its risk factors post-myocardial infarction: a prospective study. *J Acute Dis* 2022;11:26-31.
7. Behar S, Reicher-Reiss H, Shechter M, et al. Frequency and prognostic significance of secondary ventricular fibrillation complicating acute myocardial infarction: SPRINT Study Group. *Am J Cardiol* 1993;71:152-6.
8. Benito B, Josephson ME. Ventricular tachycardia in coronary artery disease. *Rev Esp Cardiol* 2012;65:939-55.
9. Mehta RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. *JAMA* 2009;301:1779-89.
10. Mehta LS, Beckie TM, DeVon HA, et al. Acute myocardial infarction in women: a scientific statement from the American Heart Association. *Circulation* 2016;133:916-47.
11. Nepper-Christensen L, Lønborg J, Høfsten DE, et al. Clinical outcome following late reperfusion with percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. *Eur Heart J Acute Cardiovasc Care* 2021;10:523-31.
12. Martinez-Navarro H, Zhou X, Bueno-Orovio A, Rodriguez B. Electrophysiological and anatomical factors determine arrhythmic risk in acute myocardial ischemia and its modulation by sodium current availability. *Interface Focus* 2021;11:20190124.
13. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. *N Engl J Med* 2001;345:1473-82.
14. Suryanarayana P, Garza HK, Klewer J, Hutchinson MD. Electrophysiologic considerations after sudden cardiac arrest. *Curr Cardiol Rev* 2018;14:102-8.
15. King GS, Goyal A, Grigorova Y, et al. Antiarrhythmic medications. Treasure Island (FL): StatPearls Publishing; 2023.
16. Zijlstra F, de Boer MJ, Hoorntje JC, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. *N Engl J Med* 1993;328:680-4.
17. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. *JAMA* 1997; 278:2093-8.
18. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. *Lancet* 2003;361:13-20.
19. Hindricks G, Lenarczyk R, Kalarus Z, et al. Prevention of sudden cardiac death by the implantable cardioverter-defibrillator. *Pol Arch Intern Med* 2018;128:764-70.
20. Tran HV, Lessard D, Tisminetzky MS, et al. Trends in length of hospital stay and the impact on prognosis of early discharge after a first uncomplicated acute myocardial infarction. *Am J Cardiol* 2018;121:397-402.



21. Salam AM, Salim I, Kaddoura R, et al. Hypertension in Middle Eastern Arab and South Asian patients with atrial fibrillation: from a 20-year hospital registry in Qatar (1990-2010). *Heart Views* 2022;22:256-63.
22. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). *Circulation* 2018;138:e618-51.
23. Abid AR, El-Menyar A, Singh R, et al. Patterns and outcomes of obesity using body mass index in patients hospitalized with acute cardiovascular disorders: a retrospective analysis of 7284 patients in a Middle Eastern country. *J Clin Med* 2023;12:7263.
24. El-Menyar AA, Albinali HA, Bener A, et al. Prevalence and impact of diabetes mellitus in patients with acute myocardial infarction: a 10-year experience. *Angiology* 2009;60:683-8.
25. El-Menyar A, Al Habib KF, Zubaid M, et al. Utility of shock index in 24,636 patients presenting with acute coronary syndrome. *Eur Heart J Acute Cardiovasc Care* 2020;9:546-56.
26. Villareal RP, Woodruff AL, Massumi A. Gender and cardiac arrhythmias. *Tex Heart Inst J* 2001;28:265-75.
27. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. *JAMA* 1994;271:840-4.
28. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. *Circulation* 2019;139:e56-528. Erratum in: *Circulation* 2020;141:e33.
29. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. *Circulation* 2014;130:2071-104. Erratum in: *Circulation* 2014;130:e270-1.
30. Hedayatnia M, Asadi Z, Zare-Feyzabadi R, et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. *Lipids Health Dis* 2020;19:42.
31. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with MI in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364:937-52.
32. Mehreen T, Ishtiaq W, Rasheed G, et al. In-hospital mortality among critically ill patients with atrial fibrillation (AF) versus patients without AF. *Cureus* 2021;13:e18761.
33. Patel U, Desai R, Munshi R, et al. Burden of arrhythmias and associated in-hospital mortality in acute decompensated diabetes mellitus. *Proc (Bayl Univ Med Cent)* 2021;34:545-9.
34. De la Fuente-Martínez J, Infante-Valenzuela A, Martínez-Roque D, et al. Impact of arrhythmia in-hospital mortality in acute ischemic stroke patients: a retrospective cohort study in northern Mexico. *J Stroke Cerebrovasc Dis* 31:106259.
35. Soliman EZ, Safford MM, Muntner P, et al. Atrial fibrillation and the risk of myocardial infarction. *JAMA Intern Med* 2014;174:107-14. Erratum in: *JAMA Intern Med* 2014;174:308.
36. Koplan BA, Stevenson WG. Ventricular tachycardia and sudden cardiac death. *Mayo Clin Proc* 2009;84:289-97. Erratum in: *Mayo Clin Proc* 2009;84:483.
37. Shirafkan A, Mehrad M, Gholamrezanezhad A, Shirafkan A. Conduction disturbances in acute myocardial infarction: a clinical study and brief review of the literature. *Hellenic J Cardiol* 2009;50:179-84.
38. Li J, Li X, Dong S, et al. Clinical characteristics and value in early reperfusion therapy for new onset right bundle branch block in patients with acute myocardial infarction. *Exp Ther Med* 2018;15:2620-6.
39. Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. *Circulation* 2005;111:2042-9.
40. Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. *Circulation* 2005;112:3738-44.
41. Hartman MHT, Eppinga RN, Vlaar PJJ, et al. The contemporary value of peak creatine kinase-MB after ST-segment elevation myocardial infarction above other clinical and angiographic characteristics in predicting infarct size, left ventricular ejection fraction, and mortality. *Clin Cardiol* 2017;40:322-8.
42. Arakawa N, Nakamura M, Aoki H, Hiramori K. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. *Cardiology* 1994;85:334-40.
43. Nagaya N, Nishikimi T, Goto Y, et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. *Am Heart J* 1998;135:21-8.
44. Richards AM, Nicholls MG, Yandle TG, et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. *Heart* 1999;81:114-20.
45. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. *Circulation* 1998;97:1921-9.
46. Ahmad M, Mehta P, Reddivari AKR, et al. Percutaneous coronary intervention. Treasure Island (FL): StatPearls Publishing; 2023.
47. Montalescot G, Andersen HR, Antoniucci D, et al. Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction. *Heart* 2004;90:e37.
48. Joo SJ. Beta-blocker therapy in patients with acute myocardial infarction: not all patients need it. *Acute Crit Care* 2023;38:251-60.
49. Farzam K, Jan A. Beta blockers. Treasure Island (FL): StatPearls Publishing; 2023.
50. Gheorghiade M, Goldstein S. β -blockers in the post-myocardial infarction patient. *Circulation* 2002;106:394-8.
51. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. *Circulation* 1998;97:2202-12.
52. Kober L, Torp-Pedersen C, Carlsen JE. A clinical trial of ACE inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandopril cardiac evaluation (TRACE) study group. *N Eng J Med* 1995;333:1670-6.
53. Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG. Effect of Ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. *Eur Heart J* 1997;18:41-51.
54. Biswajit Das. Prevention and management of arrhythmias in acute myocardial infarction. *Int J Contemp Med Res* 2016;3:1401-5.
55. Gorenek B, Lundqvist CB, Terradellas JB, et al. Cardiac arrhythm-



- mias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. *Eur Heart J Acute Cardiovasc Care* 2015;4:386.
56. Shah JA, Naz F, Kumar Ret al. Incidence of cardiac arrhythmias in acute myocardial infarction patients undergoing primary percutaneous coronary intervention and associated outcomes during the first 24 hours. *Cureus* 2021;13:e12599.
 57. Smith GL, Masoudi FA, Shlipak MG, et al. Renal impairment predicts long-term mortality risk after acute myocardial infarction. *J Am Soc Nephrol* 2008;19:141-50.
 58. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. *Eur Heart J* 2009;30:1038-45.
 59. Travin MI, Feng D, Taub CC. Novel Imaging approaches for predicting arrhythmic risk. *Circ Cardiovasc Imaging* 2015;8:e003019.

Received: 1 December 2024; Accepted: 31 January 2025; Early view: 23 April 2025.

Contributions: Nidal Asaad, Ayman El-Menyar, Rajvir Singh, Shahul Hameed Khan: conceptualization and methodology. Rajvir Singh: formal analysis. Rajvir Singh, Betsy Varughese: data curation. Betsy Varughese: writing-original draft preparation. Ayman El-Menyar, Nidal Asaad, Rajvir Singh, Shahul Hameed Khan: writing-review and editing. Hajar AlBinali, Jassim Al Suwaidi: supervisors. All the authors have read and agreed to the published version of the manuscript.

Conflict of interest: the authors declare no conflicts of interest.

Ethics approval and consent to participate: ethical approval was obtained from the Institutional Review Board of Hamad Medical Corporation, Qatar (MRC#11355/11), as there was no direct contact with the patients, and the data were collected anonymously.

Informed consent: not applicable.

Patient consent for publication: not applicable for this registry as data was retrieved retrospectively and anonymously.

Availability of data and materials: all data are presented in the manuscript, figures, and tables. The data are available on reasonable request and after approval from the medical research center of Hamad Medical Corporation, after signing a data-sharing agreement.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

